Menu
Search
|

Menu

Close
X

Orexigen Therapeutics Inc OREX.OQ (NASDAQ Stock Exchange Global Select Market)

1.18 USD
-0.07 (-5.60%)
As of Feb 23
chart
Previous Close 1.25
Open 1.36
Volume 184,068
3m Avg Volume 65,061
Today’s High 1.36
Today’s Low 1.14
52 Week High 4.66
52 Week Low 0.80
Shares Outstanding (mil) 18.89
Market Capitalization (mil) 22.29
Forward P/E --
Dividend (Yield %) -- ( -- )

LATEST NEWS

ADVERTISEMENT

RECOMMENDATION

Sell Hold Buy
3.00 Mean rating from 1 analysts

KEY STATS

Revenue (mm, USD)
FY17
61
FY16
34
FY15
24
EPS (USD)
FY17
-8.018
FY16
-3.652
FY15
-5.270
*Note: Units in Millions of U.S. Dollars
**Note: Units in U.S. Dollars

KEY RATIOS

Price to Earnings (TTM)
vs sector
--
33.62
Price to Sales (TTM)
vs sector
0.30
8.35
Price to Book (MRQ)
vs sector
--
5.22
Price to Cash Flow (TTM)
vs sector
--
25.88
Total Debt to Equity (MRQ)
vs sector
--
15.84
LT Debt to Equity (MRQ)
vs sector
--
12.39
Return on Investment (TTM)
vs sector
-69.42
13.63
Return on Equity (TTM)
vs sector
-2,625.21
15.39

EXECUTIVE LEADERSHIP

Patrick Mahaffy
Independent Chairman of the Board, Since 2016
Salary: --
Bonus: --
Michael Narachi
President, Chief Executive Officer, Director, Since 2016
Salary: $679,639.00
Bonus: --
Jason Keyes
Chief Financial Officer, Senior Vice President, Since 2016
Salary: --
Bonus: --
Thomas Cannell
Chief Operating Officer, Executive Vice President, President - Global Commercial Products, Since 2016
Salary: $445,081.00
Bonus: --
Thomas Lynch
Executive Vice President, General Counsel, Secretary, Since 2015
Salary: $370,000.00
Bonus: --

COMPANY PROFILE

Sector: Healthcare
Industry: Biotechnology & Medical Research
Address:

3344 N Torrey Pines Ct Ste 200
LA JOLLA   CA   92037-1024

Phone: +1858.8758600

Orexigen Therapeutics, Inc. is a biopharmaceutical company. The Company is focused on the treatment of obesity. The Company's product, Contrave, is approved in the United States by the United States Food and Drug Administration as an adjunct to a reduced-calorie diet and increased physical activity for chronic weight management in adults with an initial body mass index (BMI) of 30 kilograms per square meter or greater (obese) or 27 kilograms per square meter or greater (overweight) in the presence of a weight-related comorbid condition. Contrave is a combination of generic drug components, each of which has received regulatory approval for other indications and has been commercialized in the United States and in a range of member countries of the European Union. Contrave regulates appetite and energy expenditure through central nervous system (CNS) activity. Contrave is a fixed dose combination of bupropion hydrochloride (HCl) extended release (ER) and naltrexone HCl ER.

SPONSORED STORIES